CEVEC to launch CAP-T(TM) Cell System
Industry's State of the Art Human Transient Expression Technology
With CAP-T™ customers can proceed from gene to milligram and gram amounts of protein within only two weeks. Fast process times, high yields and authentic human post-translational modifications especially with complex and highly glycosylated proteins are key features and make it an ideal tool for screening, assay development, target validation, drug discovery, early stage pre-clinical drug development, and lead optimization.
Dr. Rainer Lichtenberger, CEO of CEVEC, comments: “Starting with transient protein expression using CAP-T™ and moving forward with stable expression using CAP® cells, CEVEC is now able to offer a continuum for rapid and versatile biopharmaceutical drug development from initial research ideas up to GMP-compliant manufacturing of clinical samples and market supplies.”
CAP-T™ cells are based on CAP® cells and match all their positive features with regard to comprehensive documentation, safety, non-tumor origin, and growth as suspension culture in serum- and protein-free media optimized for industrial use. CAP-T™ is available under flexible research license arrangements.
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing complex therapeutic proteins with human glycosylation patterns. CEVEC's novel proprietary human CAP® and CAP-T(TM) expression systems are ideal for manufacturing complex biopharmaceutical molecules. CEVEC is licensing out its human cell-based expression platform as well as biological product candidates from internal development through partnerships with renowned pharmaceutical and biotech companies.
Press releases you might also be interested in
Weitere Informationen zum Thema "Forschung und Entwicklung":
ARM und NVIDIA entwickeln gemeinsam KI-Chips
Um die Entwicklung des eigenen KI-Projekts Trillium voranzutreiben, hat Prozessorentwickler ARM eine Partnerschaft mit dem GPU-Hersteller NVIDIA geschlossen. Dessen Deep-Learning-Architektur NVDLA wird fortan in die Trillium-Plattform integriert.Weiterlesen